The fundamental role of Codelac Neo (Butamirate) is commonly used to help with symptoms related to physical discomfort and symptoms that become more disruptive during flare-ups. Its primary use is considered relevant for the symptomatic treatment of dry, irritant cough.

Management of the Dry, Irritable Cough Reflex

This medicine is commonly used for managing symptoms related to heightened physiological activity, specifically the non-productive cough reflex, which is characterized by its persistent, dry, and irritating quality. It helps address symptom clusters that appear suddenly during acute respiratory infections like tracheitis and acute bronchitis. By addressing the persistent, irritating quality of the cough, the medication contributes to improved comfort during periods of heightened symptoms. This reduction in the reflex assists with managing symptoms that create noticeable physiological strain and discomfort.

Supporting Comfort in Acute Clinical Contexts

The medication is applied across domains where additional symptomatic support is needed, often when symptoms that interfere with daily functioning are present. The use in acute phases provides supportive relief when symptoms interfere with routine activities. It is applied in addressing symptoms associated with conditions involving inflammatory or irritative processes. This also makes it relevant for pre- and post-operative use, or when cough sedation is required for diagnostic procedures.

“Codelac Neo supports the patient during difficult episodes by easing distress related to the cough, contributing to improved comfort during symptomatic periods.”

Alleviating Cough-Induced Sleep Disruption

This application assists with maintaining functional stability when symptoms interfere with routine activities, such as when night-time cough is present, and contributes to improved comfort during periods of heightened symptoms. The medication is used to address these patterns of discomfort, providing support that helps ease the overall symptom burden associated with symptoms that interfere with daily functioning, such as sleep.

---

Quick Fact: Relief for Non-Productive Cough

Property	Therapeutic Focus
Primary Symptom	Persistent, dry, and irritable cough
Key Benefit	Reduction in cough frequency and intensity
Relevant Contexts	Acute respiratory infections, surgical preparation
Patient Benefit	Supports improved comfort and restful sleep

Regulatory References

1. Philippines FDA Verification Portal

Codelac Neo (Butamirate citrate) is subject to specific eligibility rules outlined in official regulatory documents. Use is contraindicated for patients with a known hypersensitivity to the active ingredient or any of the excipients. Absolute exclusion also applies to children under 3 years of age for liquid formulations, and for women in the first trimester of pregnancy.

---

Official Eligibility Restrictions

Classification	Restricted Population/Condition
Absolute Contraindication	Hypersensitivity, Children under 3 years, First Trimester of Pregnancy.
Use Not Recommended	Lactation/Breastfeeding; Concomitant use with expectorants.
Condition Restriction	Patients with hereditary fructose intolerance (due to sorbitol content).

---

Age-related eligibility permits use for adults, adolescents over 12 years, and children from 3 to 12 years using age-appropriate liquid forms. However, the label notes that safety data are lacking for patients with impaired renal or hepatic function, defining groups for whom use is not established. Use during the second and third trimesters of pregnancy is restricted to cases deemed absolutely necessary.

Interactions with other medicines and products

The official regulatory profile for Butamirate citrate (the active ingredient in Codelac Neo) defines specific interaction patterns related to its central action and metabolic clearance.

---

Pharmacodynamic and Metabolic Interaction Restrictions

Interaction Type	Interacting Substance / Category	Official Restriction / Outcome
Pharmacodynamic Conflict	Expectorants or Mucolytics	Co-administration must be avoided due to the risk of mucus stagnation in the airways, as Butamirate suppresses the cough reflex.
Metabolic Risk	Strong enzyme inhibitors	Co-administration is restricted due to the formal risk of increased exposure of butamirate caused by impaired metabolic clearance.
Additive CNS Effect	Alcohol and CNS Depressants	May result in an enhanced sedative effect when used concurrently.

---

Official Interaction Statements

The most significant restriction documented in regulatory information involves the co-administration of mucus clearance agents. The antitussive effect of Butamirate directly opposes the action of expectorants, creating a condition where mucus may stagnate in the respiratory passages. Furthermore, the official documents note a pharmacokinetic interaction risk with substances that act as strong enzyme inhibitors, which formally increases the plasma concentrations of butamirate. The official profile also includes population-specific interaction notes for individuals with hepatic or renal impairment, indicating a greater risk for accumulation due to documented alterations in clearance.

Central Modulation of the Cough Reflex Arc

This domain covers the drug's primary action as an agonist on the sigma1 receptor found in the brainstem's cough center. By binding to this target, the mechanism raises the necessary neural threshold required to trigger the cough reflex, resulting in the modulation of neural signaling that affects the frequency and intensity of reflexive respiratory events.

---

Peripheral Regulation of Airway Muscle Tone

The drug also operates in the periphery by exerting a modulatory effect that promotes the relaxation of smooth muscle within the walls of the bronchial tubes. This action decreases the tension in the airways, which influences the diameter of the airways by reducing the contractile force exerted by the surrounding muscle tissue.

---

Dual-Level Physiological Stabilization

The drug engages a dual mechanism, combining the central suppression of the reflex arc with the peripheral modulation of airway muscle contractility. This integrated action influences the function of the efferent respiratory pathways, contributing to the resulting pattern of reflexive respiratory activity.

How to Use Codelac Neo: Official Administration Guidelines

Codelac Neo (Butamirate citrate) is administered solely by the oral route as a liquid solution, typically available as a syrup (often 7.5 mg per 5 mL) or oral drops. Its usage is governed by high-level, standardized dosing regimens, with volumes and frequency prescribed according to the patient's age group.

---

Official Dosing and Frequency Patterns

The medicine is designed for multiple administrations per day, using a measuring device to ensure the correct volume is taken.

Population	Standard Dosing Regimen (7.5 mg/5 mL Syrup)	Frequency
Adults	15 mL (22.5 mg)	Up to 4 times daily (QID)
Adolescents (>12 years)	15 mL (22.5 mg)	3 times daily (TID)
Children (6–12 years)	10 mL (15 mg)	3 times daily (TID)
Children (3–6 years)	5 mL (7.5 mg)	3 times daily (TID)
Infants (Drops)	Dosed by specific drop count, varying by age	Typically 4 times daily

---

Administration Constraints and Duration

Treatment with Codelac Neo is strictly limited to the symptomatic period. The instruction mandates that the medication is not intended for prolonged use.

Crucially, it is explicitly required to avoid the simultaneous use of expectorants. This is a procedural constraint tied to proper use. If symptoms persist for longer than 4–5 days during the course of administration, the dose must not be increased; instead, clinical review is required.

Research Evidence / Overview of Studies for Codelac Neo

Evidence for Use in Managing Dry, Irritable Cough

Research has explored the use of Codelac Neo (Butamirate) in conditions characterized by dry, irritative cough. Studies used in research exploring how symptoms change over time include randomized controlled trials (RCTs), where the drug was evaluated against both inactive placebos and other active cough suppressants. The primary outcomes studied included measurements of the severity and frequency of day-time and night-time coughing episodes.

The findings from these trials describe patterns observed in the studies related to changes in cough severity scores over observation periods, typically lasting only about five to seven days. However, evidence quality varies across studies; while some trials reported measurements of symptom change, other specific controlled studies reported mixed or uncertain findings when tested under laboratory conditions.

Evidence for Use in Pre- and Post-Operative Settings

Butamirate was also evaluated in research scenarios involving cough suppression around surgical or diagnostic procedures. This application has been applied in studies examining patient-reported experiences where temporary physiological imbalance requires cough suppression. Research describes the use of Butamirate during periods of increased symptom activity, such as before or after surgery or procedures like bronchoscopy, in scenarios requiring cough control.

The evidence for this specific context is mainly derived from established clinical practice and observational settings evaluating daily-life functioning. The evidence is limited for this use, and certainty remains low regarding the existence of comparative evidence against other agents used for procedural cough sedation.

Research in Special Populations and Duration of Study

The research has explored the use of Codelac Neo in different age groups, including pediatric populations with acute cough, and adult and geriatric patient cohorts. Data show patterns related to use in both children and older adults, though studies apply only to the specific populations studied. The vast majority of research has focused on short-term symptom patterns, typically lasting less than one week. The existing evidence base provides limited information for outcomes related to the durability of response or the research exploring the use of Codelac Neo for extended periods, as follow-up durations were limited.

Key Studies & References

1. Analysis of the evidence of efficacy and safety of over-the-counter cough medications registered in Brazil
2. The effect of butamirate versus dextromethorphan was studied in patients with irritable cough. In 29 out of 30 patients treated [Regulatory Assessment Document]
3. Butacod (Butamirate Citrate) Therapeutic Group: Cough Suppressant Overview [Product Monograph detailing Pre- and Post-operative Use]

Common questions about Codelac Neo (FAQ)

---

Q: How quickly should I expect Codelac Neo to start working?

Studies on Codelac Neo indicate that peak plasma levels of the primary active metabolite are typically reached in approximately 1.5 hours after taking the oral syrup. This pharmacokinetic measurement helps describe the timeframe in which the medicine reaches its highest measured concentration in the body.

---

Q: What is the difference between Codelac Neo and typical cold medicine?

Official classification defines Codelac Neo as a non-opioid antitussive (cough suppressant) agent. Its sole purpose is the symptomatic relief of a non-productive (dry) cough. This distinguishes it from many typical cold medicines, which are multi-symptom products designed to treat fever, nasal congestion, and other associated symptoms.

---

Q: Do I need a prescription from a doctor to get Codelac Neo?

Regulatory documents confirm Codelac Neo as a designated medicinal product, meaning its use is regulated. Its specific availability—whether as a prescription-only or over-the-counter medicine—can vary depending on the country or region and the local health authority’s specific rules.

---

Q: Are there any major food or drink restrictions while using Codelac Neo?

Official regulatory information documents the need to avoid alcohol during treatment because of the potential for enhanced sedative effects, which may increase drowsiness. Regarding food, patient information for certain liquid formulations indicates that the medicine may generally be taken with or without food.

---

Q: Can Codelac Neo affect my ability to drive or operate machinery?

Regulatory information includes a note of caution. Because documented side effects of this medicine include drowsiness and dizziness, official warnings recommend that patients avoid driving or operating machines until they have observed how the medicine affects their alertness.

---

Q: How long does the effect of one dose of Codelac Neo typically last?

The apparent elimination half-life of the medicine is described as approximately 6 hours. This is a measure of the time it takes for the drug's concentration in the body to be reduced by half, and it is the value that informs the required frequency of administration (multiple times daily).

---

Q: What should I do if I think I've taken too much Codelac Neo?

Symptoms of overdose may include drowsiness, nausea, vomiting, diarrhea, dizziness, and low blood pressure. The required action is to seek immediate medical attention. Official documents describe that standard medical treatment may include monitoring of vital signs and supportive measures such as administration of activated charcoal.

---

Q: Why do official documents advise caution for people with certain health conditions when taking Codelac Neo?

Official documentation notes that safety data are lacking for patients with impaired renal (kidney) or hepatic (liver) function. The reason for this caution is the potential for the medicine and its metabolites to accumulate in the body when these organs are not functioning fully, which may lead to increased adverse effects.

---

Q: Is there a generic version of Codelac Neo?

Codelac Neo is a specific brand name for the active pharmaceutical ingredient Butamirate citrate. While it is a specific product name, this active ingredient is a synthetic compound and is marketed globally under various different brand names in various regions.

---

Q: Can Codelac Neo be taken with certain chronic medications?

Regulatory information advises against co-administration with two main types of chronic medicines: strong enzyme inhibitors and medicinal products that have a narrow therapeutic index (a small difference between an effective and toxic dose). This is due to the potential for an interaction that could alter the concentration of either drug.

---

Q: Has Codelac Neo been approved by the FDA or similar international bodies?

The active ingredient, Butamirate, is regulated and marketed in many countries globally under the authority of national bodies like those in Europe and Asia. However, the medicine is not currently approved for marketing by the U.S. Food and Drug Administration (FDA).

---

Q: Does taking Codelac Neo with food change how it works?

The official product information for some liquid formulations indicates that the medicine may be taken by mouth with or without food. There is typically no explicit warning that food must be consumed or avoided to ensure the drug’s effectiveness.

---

Q: Can I take Codelac Neo if I'm taking herbal supplements?

Regulatory documents state that the effects of many other medicinal products, including herbal supplements, on Codelac Neo's action have not been fully investigated. This uncertainty suggests that co-administration with other substances warrants careful review.

---

Q: What happens to Codelac Neo in the body?

The official pharmacokinetic profile indicates the medicine is well absorbed after being taken orally. Once absorbed, it is primarily metabolized in the liver to form active substances, and these metabolites are then mostly eliminated from the body through the urine.

---

Q: Does Codelac Neo affect blood pressure or heart rate?

At the recommended therapeutic doses, cardiovascular effects are not listed as common or rare side effects. However, official documents indicate that a severe overdose of the medicine may lead to symptoms including hypotension (low blood pressure).

---

Q: Is Codelac Neo associated with any specific warnings for people with diabetes?

The medicine contains the excipient sorbitol, which is a type of sugar substitute. Official documents include a warning that patients with a condition called hereditary fructose intolerance must not use this medicine because of the sorbitol content.

---

Q: What is the function of the non-active ingredients in Codelac Neo?

Non-active ingredients, or excipients, are added to the formulation to help stabilize the medicine, improve its taste, or ensure the active ingredient is delivered properly. Warnings are sometimes provided for specific excipients, such as sorbitol, for those with certain health conditions.

How to Store and Dispose of Codelac Neo?

The official storage and disposal requirements for Codelac Neo (butamirate citrate) are defined by regulatory labeling to maintain the product's quality and ensure safe handling.

---

Storage Conditions

• Temperature: Store the medicine at a temperature not exceeding 30 C, and some formulations require storage below 25 C.
• Protection: The product must be stored in its original container and protected from both light and moisture.
• Child Safety: It must be kept out of the sight and reach of children.
• Stability: The syrup formulation has a shelf life of 6 months after first opening the bottle.

---

Disposal Instructions

• Expired or unused medicine must not be disposed of via wastewater or household waste.
• Patients must ask their pharmacist how to properly throw away any medicine that is no longer needed.